Comparison of the efficacy and safety of programmed cell death protein 1 inhibitors combined with albumin-paclitaxel with or without platinum in the treatment of advanced metastasis or recurrent cervical cancer
Journal Title: Chinese Journal of Clinical Research - Year 2024, Vol 37, Issue 5
Abstract
<b>Objective</b> To compare the efficacy and safety of programmed cell death protein 1 (PD-1) inhibitor + albumin paclitaxel and platinum + PD-1 inhibitor + albumin-paclitaxel in the treatment of advanced metastasis or recurrent cervical cancer. <b>Methods</b> The clinical data of patients who had advanced metastatic or recurrent cervical cancer were treated with PD-1 inhibitor + albumin paclitaxel + platinum (group A) or anti-PD-1 + albumin-bound paclitaxel (group B) in more than second-line therapy in the Affiliated Cancer Hospital of Nanjing Medical University from September 2018 to December 2022 were retrospectively analyzed. The objective response rate (ORR), progression-free survival (PFS) and the incidence of adverse reactions between the two groups were compared. <b>Results</b> A total of 54 patients were collected, 37 in group A and 17 in group B. The median age was 53 years old, and the average follow-up time was 10 months. Among the patients, 45 cases were squamous cell carcinoma, 6 cases were adenocarcinoma, 1 case was adenosquamous carcinoma, and 2 cases were neuroendocrine small cell carcinoma. There was no statistically significant difference in the ORR between group A and group B (35.30% vs 35.14%, P>0.05). There was no statistical significant difference in PFS between group A and group B (11.7 month vs 7.3 month, P>0.05). The differences in the incidence of adverse reactions, the incidence of adverse reactions with grade 3 and above, and the incidence of immune-related adverse reactions between the two groups were not statistically significant (P>0.05). <b>Conclusion</b> The PD-1 inhibitor + albumin paclitaxel + platinum regimen does not increase the efficacy compared with the PD-1 inhibitor + albumin paclitaxel regimen in more than second-line therapy of advanced metastatic and recurrent cervical cancer.
Authors and Affiliations
SHEN Jing*, XU Jingjing, LYU Mengmeng, WU Dongchen, WANG Jinhua
Keywords
Related Articles
- EP ID EP736341
- DOI 10.13429/j.cnki.cjcr.2024.05.038
- Views 5
- Downloads 0
Research progress of left bundle branch block
Left bundle branch block (LBBB) is an important cause of heart failure. When LBBB occurs, the excitation sequence of the left ventricle changes, leading to the change of cardiac systolic pattern, resulting in cardiac ele...
Research progress in sensitivity to inhalation anesthetics
Inhalation anesthetics have both sedative, analgesic and muscle relaxing effects,and are widely used in clinical practice. Hypersensitivity to inhalation anesthetics predicts poor postoperative outcomes. Current studies...
Overview of post-marketing research on medicines and medical devices
Post-marketing research on medicines and medical devices is an important aspect of product lifecycle management. Based on literature research and expert consultation, this article proposes a conceptual system for post-ma...
Role and mechanism of mast cells in solid tumors
Mast cells are a type of innate immune cells, and have long been considered to be related to the pathogenesis of allergic and autoimmune diseases. However, in recent years, a number of studies have found that mast cells...
Correlation between triglyceride-glucose index and atherosclerosis in type 2 diabetes mellitus
Objective To investigate the the clinical application of triglyceride-glucose (TyG) index and its correlation with atherosclerosis in patients with type 2 diabetes mellitus (T2DM). Methods From January 2020 to December...